|1.||Kozmin, Stanislav G: 3 articles (10/2013 - 06/2007)|
|2.||Schaaper, Roel M: 3 articles (10/2013 - 06/2007)|
|3.||Schwarz, Günter: 2 articles (01/2011 - 12/2002)|
|4.||Reiss, Jochen: 2 articles (12/2010 - 12/2002)|
|5.||Grell, Tsehai A J: 1 article (02/2015)|
|6.||Drennan, Catherine L: 1 article (02/2015)|
|7.||Goldman, Peter J: 1 article (02/2015)|
|8.||Kip, Gülay: 1 article (11/2014)|
|9.||Şahin, Şaziye: 1 article (11/2014)|
|10.||Alkan, Metin: 1 article (11/2014)|
11/01/2014 - "Molybdenum cofactor (MC) deficiency is defined as a progressive neurodegenerative and neurometabolic disease, characterized by convulsions, severe mental and motor retardation resistant to the treatment. "
12/01/2010 - "Molybdenum cofactor (Moco) deficiency is a rare neurometabolic disorder, characterized by neurological impairment and refractive seizures, due to toxic accumulation of sulfite in the brain. "
06/01/1993 - "Two new cases are reported, and the literature on neonatal convulsions due to molybdenum-cofactor and sulphite deficiencies is reviewed. "
12/15/2002 - "The absence of active sulfite oxidase-a molybdenum cofactor-dependent enzyme-results in neonatal seizures and early childhood death. "
12/01/1998 - "Molybdenum cofactor (MoCo) deficiency is a rare and devastating disease resulting in neonatal seizures and other neurological symptoms identical to those of sulphite oxidase deficiency. "
06/01/2007 - "Lack of molybdenum cofactor (MoCo) in Escherichia coli and related microorganisms was found to cause hypersensitivity to certain N-hydroxylated base analogs, such as HAP (6-N-hydroxylaminopurine). "
06/01/2000 - "Hypersensitivity of Escherichia coli Delta(uvrB-bio) mutants to 6-hydroxylaminopurine and other base analogs is due to a defect in molybdenum cofactor biosynthesis."
10/01/2013 - "Lack of molybdenum cofactor (Moco) in Escherichia coli leads to hypersensitivity to the mutagenic and toxic effects of N-hydroxylated base analogs, such as 6-N-hydroxylaminopurine (HAP). "
04/01/2008 - "We have shown previously that lack of molybdenum cofactor (MoCo) in Escherichia coli leads to hypersensitivity to the mutagenic and toxic effects of N-hydroxylated base analogues, such as 6-N-hydroxylaminopurine (HAP). "
|3.||Contagious Ecthyma (Orf)
07/01/2005 - "aeruginosa genome sequence revealed that PA3028, an ORF with high similarity on the amino acid level to molybdenum cofactor biosynthesis protein A2 (encoded by moeA2), was the target of mini-Tn5 in the mutant. "
12/01/1999 - "Instead, all 5 ORFs downstream of ORF 6 are homologous to genes reported for molybdopterin biosynthesis, unlike the genomic organization already determined for the respiratory and assimilatory nitrate-reduction systems. "
01/01/1999 - "One ORF is related to enzymes involved in biosynthesis of PQQ or molybdopterin cofactors. "
|4.||Mental Retardation (Idiocy)
12/01/1993 - "Although XO deficiency is relatively benign, patients with isolated deficiencies of SO or molybdenum cofactor exhibit mental retardation, neurologic problems, and ocular lens dislocation. "
04/01/2005 - "Molybdenum cofactor and isolated sulphite oxidase deficiencies are two related rare autosomal recessive diseases characterized by severe neurological abnormalities, dislocated lens and mental retardation. "
|3.||Proteins (Proteins, Gene)
|5.||Connective Tissue Growth Factor
|6.||Messenger RNA (mRNA)
|9.||Heat-Shock Proteins (Heat-Shock Protein)
|10.||Butirosin Sulfate (Butirosin)